Trial Profile
Effects of acute and chronic oral administration of S 44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1 - A randomized, parallel-group, international multicentre study including a 8-week double-blind placebo controlled period followed by a 8-week single-blind period - Phase II exploratory study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2019
Price :
$35
*
At a glance
- Drugs Aladorian (Primary)
- Indications Polymorphic catecholergic ventricular tachycardia
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Servier
- 05 Sep 2019 Status changed from recruiting to discontinued.
- 23 Jun 2012 Additional locations (Brazil, Canada, Czech Republic, Hungary, Italy, Slovakia and Taiwan ) added as reported by European Clinical Trials Database.
- 21 Apr 2012 Planned end date 1 Jun 2013 added as reported by European Clinical Trials Database record.